Bioequivalence evaluation of two rosiglitazone tablet formulations

Arzneimittel-Forschung/Drug Research

Volumn 56, Issue 11, 2006, Pages 740-743

  Yusuf, Ahmed ^a   Al Gaai, Eman ^a   Hammami, Muhammad M ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Antidiabetics; CAS 122320 73 4; Rosiglitazone, bioavailability, bioequivalence, pharmacokinetics

Indexed keywords

CAS 122320 73 4; GLIBENCLAMIDE; ROSIGLITAZONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET FORMULATION;

EID: 33845439581     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296784     Document Type: Article

References (11)

1. St. John Sutton, M., Rendell, M., Dandona, P. et al., A Comparison of the Effects of Rosiglitazone and Glyburide on Cardiovascular Function and Glycemic Control in Patients With Type 2 Diabetes. Diabetes Care 25, 2064 (2002)
2. Wagstaff, A. J., Goa, K. L., Rosiglitazone: A Review of its Use in the Management of Type 2 Diabetes Mellitus. Drugs 62, 1805 (2002)
3. Park, J. Y., Kim, K. A., Kyoung, M. H. et al., Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin. Pharmacol. Ther. 75, 157 (2004)
4. RxList - the internet drug index. http://www.rxlist.com/cgi/generic3/ avandamet_cp.htm
5. Kolte, B. L., Raut, B. B., Deo, A. A. et al., Liquid chromatographic method for the determination of rosiglitazone in human plasma. J. Chromatogr. B 788, 37 (2003)
6. [6) Sauter, R., Steinijans, V. W., Diletti, E. et al., Presentation of results from bioequivalence studies. Int. J. Clin. Pharmacol. Ther. Toxicol. 30, 233 (1992)
7. Schuirmann, D.J., A comparison of two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharmacokinet. Biopharm. 15, 657 (1987)
8. Food and Drug Administration. Guidance for industry: bioavailability and bioequivalence studies for oral administration drug products. Rockville, MD, USA (2003); http://www.fda.gov/cder/gudance/index.htm
9. Drkoop. Avandia clinical pharmacology. http://www.drkoop.com/druglibrary/ 93/avandia-clinicalpharmacology.html
10. Rao, M. N. V. S., Mullangi, R., Katneni, K. et al., Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. J. Clin. Pharmacol. 42, 670 (2002)
11. Health Canada. Guidance for industry: Conduct and Analysis of Bioavailability and Bioequivalence Studies - Part B: Oral Modified Release Formulations. Ottawa, Ontario, Canada (1996); http://www.hc-sc.gc.ca/dhp-mps/ prodpharma/applic-demande/guide-ld/bio/bio-b_e.html